Patient characteristics and prestudy prognostic factors by study
Factor . | TT1, no./N (%) . | TT2 No THAL, no./N (%) . | P . |
|---|---|---|---|
| Median age, y | 51.0 | 56.6 | <.001* |
| Age at least 65 y | 21/231 (9) | 72/345 (21) | <.001 |
| Age at least 70 y | 2/231 (1) | 26/345 (8) | <.001 |
| White | 206/231 (89) | 308/345 (89) | .97 |
| IgA isotype | 41/231 (18) | 76/345 (22) | .21 |
| Female | 88/231 (38) | 135/345 (39) | .80 |
| CRP ≥ 8 mg/L | 70/223 (31) | 127/339 (37) | .14 |
| B2M ≥ 3.5 mg/L | 95/229 (41) | 126/345 (37) | .23 |
| Bone marrow plasma cells > 30% | 135/231 (58) | 170/291 (58) | .99 |
| Albumin < 35 g/L (3.5 g/dL) | 62/231 (27) | 59/343 (17) | .005 |
| Hemoglobin < 100 g/L (10 g/dL) | 78/231 (34) | 80/345 (23) | .005 |
| Creatinine ≥ 176.8 μM/L (2 mg/dL) | 22/231 (10) | 37/339 (11) | .59 |
| LDH above upper limit of normal | 49/230 (21) | 86/344 (25) | .31 |
| Cytogenetic abnormalities (CAs) | 74/231 (32) | 104/339 (31) | .73 |
| ISS Stage 1 | 110/229 (48) | 195/343 (57) | .070 |
| Stage 2 | 74/229 (32) | 83/343 (24) | — |
| Stage 3 | 45/229 (20) | 65/343 (19) | — |
| One cycle of prior therapy | 76/231 (33) | 88/345 (26) | .054 |
| Completed Tx1 | 195/231 (84) | 292/345 (85) | .94 |
| Completed Tx2 | 165/231 (71) | 235/345 (68) | .40 |
Factor . | TT1, no./N (%) . | TT2 No THAL, no./N (%) . | P . |
|---|---|---|---|
| Median age, y | 51.0 | 56.6 | <.001* |
| Age at least 65 y | 21/231 (9) | 72/345 (21) | <.001 |
| Age at least 70 y | 2/231 (1) | 26/345 (8) | <.001 |
| White | 206/231 (89) | 308/345 (89) | .97 |
| IgA isotype | 41/231 (18) | 76/345 (22) | .21 |
| Female | 88/231 (38) | 135/345 (39) | .80 |
| CRP ≥ 8 mg/L | 70/223 (31) | 127/339 (37) | .14 |
| B2M ≥ 3.5 mg/L | 95/229 (41) | 126/345 (37) | .23 |
| Bone marrow plasma cells > 30% | 135/231 (58) | 170/291 (58) | .99 |
| Albumin < 35 g/L (3.5 g/dL) | 62/231 (27) | 59/343 (17) | .005 |
| Hemoglobin < 100 g/L (10 g/dL) | 78/231 (34) | 80/345 (23) | .005 |
| Creatinine ≥ 176.8 μM/L (2 mg/dL) | 22/231 (10) | 37/339 (11) | .59 |
| LDH above upper limit of normal | 49/230 (21) | 86/344 (25) | .31 |
| Cytogenetic abnormalities (CAs) | 74/231 (32) | 104/339 (31) | .73 |
| ISS Stage 1 | 110/229 (48) | 195/343 (57) | .070 |
| Stage 2 | 74/229 (32) | 83/343 (24) | — |
| Stage 3 | 45/229 (20) | 65/343 (19) | — |
| One cycle of prior therapy | 76/231 (33) | 88/345 (26) | .054 |
| Completed Tx1 | 195/231 (84) | 292/345 (85) | .94 |
| Completed Tx2 | 165/231 (71) | 235/345 (68) | .40 |
— indicates not applicable.
Wilcoxon 2-sample test, otherwise chi-square test for independence.